F
Frédéric Maudoux
Researcher at Université libre de Bruxelles
Publications - 4
Citations - 565
Frédéric Maudoux is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Immunogenicity & Papillomavirus E7 Proteins. The author has an hindex of 4, co-authored 4 publications receiving 546 citations.
Papers
More filters
Journal ArticleDOI
HIV-1 tat transcriptional activity is regulated by acetylation.
Rosemary Kiernan,Caroline Vanhulle,Lou Schiltz,Emmanuelle Adam,Hua Xiao,Frédéric Maudoux,Claire Calomme,Arsène Burny,Yoshihiro Nakatani,Kuan-Teh Jeang,Monsef Benkirane,Carine Van Lint +11 more
TL;DR: It is shown that p300 and PCAF also directly acetylate Tat, suggesting that acetylation of Tat regulates two discrete and functionally critical steps in transcription, binding to an RNAP II CTD‐kinase and release of Tat from TAR RNA.
Journal ArticleDOI
Phase i/ii trial of immunogenicity of a human papillomavirus (hpv) type 16 e7 protein-based vaccine in women with oncogenic hpv-positive cervical intraepithelial neoplasia
Sophie Hallez,Philippe Simon,Frédéric Maudoux,Jean Doyen,Jean Christophe Noël,Aude Beliard,Xavier Capelle,Frédéric Buxant,Isabelle Fayt,Anne-Cécile Lagrost,Pascale Hubert,Colette Gerday,Arsène Burny,Jacques Boniver,Jean-Michel Foidart,Philippe Delvenne,Nathalie Jacobs +16 more
TL;DR: The encouraging results obtained from this study performed on a limited number of subjects justify further analysis of the efficacy of the PD-E7/AS02B vaccine in CIN patients.
Journal ArticleDOI
DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Jean-Marc Brulet,Frédéric Maudoux,Séverine Thomas,Kris Thielemans,Arsène Burny,Oberdan Leo,Françoise Bex,Sophie Hallez +7 more
TL;DR: It is suggested that an efficient anti‐tumor response can be induced in vivo by DNA constructs encoding for E7 protein forms localizing at the endosomal compartment.
Journal Article
Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
Sophie Hallez,Jean-Marc Brulet,Caroline Vandooren,Frédéric Maudoux,Séverine Thomas,Michel Heinderickx,Alex Bollen,Ruddy Wattiez,Alain Jacquet +8 more
TL;DR: E7delta21-26 could represent a safe and efficient vaccine candidate against E7-containing tumour cells and therapeutic vaccination with adjuvant-modified E7 suppressed or significantly decreased C3 tumour outgrowth.